As further detailed in the complaint, as the true information about the company’s higher medical costs was disclosed as Agilon reported lower than expected financial results and expectations for future revenue, shares of the company’s stock significantly declined in value, harming the company’s long-term investors.  Specifically, Agilon’s stock price declined approximately 85% in value during the relevant period from over $44.00 per share to less than $6.50 per share, a decline of over $38.00 per share.